CHAMOUNE ALCE: Open Payments
NPI 1912635681 · WARWICK, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$386 in 17 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $286 · 2025 $386
Food & beverage: $386
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $80 |
| Novo Nordisk Inc | 3 | $68 |
| Lilly USA, LLC | 2 | $59 |
| Novartis Pharmaceuticals Corporation | 3 | $52 |
| Corcept Therapeutics | 1 | $23 |
| Verona Pharma, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $23 |
| PFIZER INC. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
Products named: MOUNJARO, LEQVIO, BREZTRI, AIRSUPRA, Korlym, Ohtuvayre, Fluad, Kerendia.
Industry payments across RI — which companies pay providers there.
